April 4, 2025 06:53 AM EDTUpdated 08:10 AM

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Ayisha Sharma

News Reporter

Eli Lilly is licensing Sangamo Therapeutics’ AAV capsid for an undisclosed CNS disease target, and the $18 million upfront fee should give the beleaguered biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Trump administration leaves obesity coverage expansion out of new Medicare rule

Marks was asked to provide non-existent vaccine risk data: WSJ

Secretive Chinese startup begins first-ever clinical trial of circular RNA therapy

Kennedy team defends Marks firing, while 20% of staff cuts may be 'mistakes'

Novavax’s held-up approval package may signal warning for Covid vaccine makers

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Eli Lil­ly pays strug­gling Sang­amo $18M up­front to tap gene ther­a­py cap­sid

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid